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Abstract: Signaling pathways regulated by the phosphoinositide 3-kinase (PI3K) enzymes have a
well-established role in cancer development and progression. Over the past 30 years, the therapeutic
potential of targeting this pathway has been well recognized, and this has led to the development of a
multitude of drugs, some of which have progressed into clinical trials, with few of them currently
approved for use in specific cancer settings. While many inhibitors compete with ATP, hence
preventing the catalytic activity of the kinases directly, a deep understanding of the mechanisms
of PI3K-dependent activation of its downstream effectors led to the development of additional
strategies to prevent the initiation of this signaling pathway. This review summarizes previously
published studies that led to the identification of inositol polyphosphates as promising parent
molecules to design novel inhibitors of PI3K-dependent signals. We focus our attention on the
inhibition of protein–membrane interactions mediated by binding of pleckstrin homology domains
and phosphoinositides that we proposed 20 years ago as a novel therapeutic strategy.
Keywords: inositol polyphosphates; inositol 1,3,4,5,6-pentakisphosphate; phosphoinositides;
phosphoinositide 3-kinase; pleckstrin homology domain
1. Phosphoinositides and Protein Binding Domains
Phosphoinositides consist of a water-soluble inositol head linked to a diacylglycerol by a
phosphodiester linkage (Figure 1) [1]. Although nine isomeric forms of inositol exist, myo-inositol
is the most commonly used in nature [2]. The majority of phosphoinositides possess the same acyl
chains (stearoyl in the 1-position and arachidonoyl in the 2-position) and, historically, little attention
was paid to determining the physiological relevance of such a specific enrichment [3]. Recently, thanks
to improved methodologies, there is an increased interest to understand the importance of differential
acyl chains within phosphoinositides. Traditionally, however, phosphoinositides have been classified
on the basis of the specific phosphorylation of their myo-inositol head (Figure 1).
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Figure 1. (a) Schematic representation of Phosphatidylinositol, showing the unphosphorylated
hydroxyls within the myo-inositol head group, the phosphodiester bond (in red), and the attached
diacylglycerol. (b) Generic structure of a diacylglycerol. Most phosphoinositides possess stearoyl (R1)
and arachidonoyl (R2) chains.
While the precursor and most abundant member of the family, Phosphatidylinositol,
is unphosphorylated (Figure 1a), differential phosphorylation of the hydroxyls at the 3-, 4-, and
5-position of myo-inositol leads to seven derivatives (Figure 2), all of which have been detected in all
higher eukaryotes [4].
Figure 2. Schematic representation of the seven phosphoinositides.
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Intracellular localization of specific kinases and phosphatases and/or their relocation upon cellular
stimulation regulate synthesis and degradation of localized pools of phosphoinositides. Such a
spatial and often temporal regulation makes phosphoinositides, despite being only minor components
of cellular membranes, key modulators of several physiological processes, mostly by controlling
compartmentalization and, often, activation of diverse cellular proteins [4]. This is achieved through
their binding to specific domains within their target proteins, which, in turn, retains/relocates these
proteins to the specific cellular compartment where their function is required. As these protein domains
bind to the soluble head group, the distinct phosphorylation pattern within the inositol ring can
guarantee specificity of interaction between one phosphoinositide and its effector protein. An example
of such a selective interaction is provided by proteins that possess Fab1/YOTB/Vac1/EEA1 (FYVE)
domains, zinc finger modules that exist as single or tandem repeats and that can specifically bind
Phosphatidylinositol 3-phosphate (PtdIns3P) [5]. On the other hand, some protein domains do not
appear to be specific for one phosphoinositide alone, as in the case of mammalian Phox homology (PX)
domains, which have been found to bind PtdIns3P but also Phosphatidylinositol 3,5-bisphosphate and
Phosphatidylinositol 3,4-bisphosphate (PtdIns(3,4)P2) [6]. Moreover, there are only few examples of
protein domains for which binding to phosphoinositides is sufficient to guarantee a strong membrane
interaction of the protein. For example, most FYVE domain-containing proteins require dimerization
of these domains to be targeted to PtdIns3P-enriched endosomes successfully, although this may be
crucial only for a subset but not for all FYVE domains [7]. Similarly, there are only few examples of
PX domains able to bind PtdIns3P with high affinity, and the majority of them are recruited to the
membrane only as part of a multicomplex [4].
Amongst all phosphoinositide-binding domains, pleckstrin homology (PH) domains have received
considerable attention since their first identification as a structural protein module of approximately
100 amino acid residues occurring twice in pleckstrin in 1993 [8,9]. Despite a poorly conserved primary
structure, all PH domains possess a similar tertiary structure [10]. Although originally PH domains
were thought to bind proteins and indeed some protein interactions have been described [11], attention
towards them grew when they were recognized as phosphoinositide-binding domains. Only a few PH
domains, however, have shown a clear stereospecificity and high binding affinity for phosphoinositides.
On the basis of this, almost 20 years ago, we classified them into three groups: (i) PH domains with high
affinity for a specific phosphoinositide, (ii) PH domains with low specificity and/or affinity, and (iii)
PH domains that bind non-specifically to phosphoinositides [11]. Binding of phosphoinositides to
group 1 PH domains is sufficient to relocate/retain the host protein to the membrane. On the other
hand, the weak interaction between phosphoinositides and group 2 PH domains requires additional
mechanisms to guarantee a stable recruitment of the protein to the membrane [6,11]. We proposed
a mechanism of cooperative binding between lipids or lipid and proteins [11]. This mechanism of
lipid cooperativity has been subsequently demonstrated [12,13]. More recently, it has been found that
the interaction of a PH domain with a membrane requires a localized cluster of phosphoinositide
molecules in an anionic lipid-enriched microenvironment [14,15].
An important feature of many PH domains is their ability to bind phosphoinositides as well as
their corresponding water-soluble inositol polyphosphates, often with a similar affinity/specificity.
This is not common to all phosphoinositide-binding domains; for instance, FYVE domains were
reported to bind more strongly to membrane-embedded PtdIns3P than to the isolated head group
Inositol 1,3-bisphosphate [6,7]. This feature has been crucial for the development of targeted strategies
to stop/prevent PH domain/phosphoinositide interactions, as we discuss later.
2. Akt PH Domain and PtdIns(3,4,5)P3: A “Textbook” Example of Phosphoinositide-Dependent
Regulation of Signaling Pathways and Cellular Functions
Amongst the seven phosphoinositides, the central role of Phosphatidylinositol 3,4,5-trisphosphate
(PtdIns(3,4,5)P3) in cell signaling was immediately recognized once it emerged that this lipid was
almost undetectable in unstimulated normal cells, and it was synthesized very rapidly upon cellular
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stimulation before being degraded quickly, showing all features of a second messenger. PtdIns
(3,4,5)P3 is one of the three lipid products of a family of enzymes named Phosphoinositide 3-kinases
(PI3Ks) because of their ability to catalyze phosphorylation at the inositol 3′ position within selective
phosphoinositides [16,17]. Their substrate specificity, together with their structure, has provided the
basis for grouping the eight mammalian PI3Ks into three classes [18–20]. Specifically, synthesis of
PtdIns(3,4,5)P3 in vivo is mediated by the class I subgroup, dimers of a regulatory protein, and one of
four catalytic subunits, namely, p110α, p110β, p110δ, and p110γ [19]. By synthesizing PtdIns(3,4,5)P3,
class I PI3Ks modulate activation of several target proteins, ultimately regulating many cellular
functions, including growth, survival, migration, and metabolism [21–23].
The most studied and best characterized amongst all proteins activated by class I PI3Ks is the
Serine/Threonine kinase Akt [24]. In fact, the class I PI3K/PtdIns(3,4,5)P3-dependent Akt activation is
one of the best-known examples of a phosphoinositide-mediated protein activation, often used as the
canonical example of how stimuli (such as growth factors, hormones, etc.) can activate intracellular
signaling pathways and functions. Specifically, upon cellular stimulation, class I PI3Ks catalyze the
phosphorylation of Phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2), leading to the synthesis
of PtdIns(3,4,5)P3 at the plasma membrane. PtdIns(3,4,5)P3 can then bind Akt PH domain and
induce translocation of the kinase to the plasma membrane. Once at the membrane, Akt is activated
via phosphorylation at its residue Thr308 by 3-phosphoinositide-dependent kinase 1 (PDK1), itself
possessing a PtdIns(3,4,5)P3-binding PH domain. Additional kinases, including the mechanistic target
of rapamycin (mTOR) complex 2, further phosphorylate Akt at Ser473, providing full activation of the
enzyme. Importantly, binding to PtdIns(3,4,5)P3 not only localizes Akt to the plasma membrane but it
also affects the interaction between its PH and kinase domains [25]. Several studies have demonstrated
that such an interaction is crucial for Akt phosphorylation and subsequent dissociation from the
plasma membrane, highlighting the importance of this allosteric regulation for Akt activation [25,26].
In particular, it was reported that Akt exists in a complex with PDK1, which is inactive when Akt PH and
kinase domains interact, in a so-called “PH-in” conformer [27]. Upon Akt recruitment to the membrane,
a conformational change occurs, and in such a “PH-out” conformer, PDK1 can phosphorylate Akt [27].
Once activated, Akt can phosphorylate and activate/inactivate more than 100 substrates, controlling
a multitude of cellular functions including cell survival, cell cycle, cell growth, glucose transport,
and storage [28]. Considering its ability to regulate a vast array of cellular functions, it is not surprising
that Akt activation is tightly regulated, mainly via a strict temporal regulation of PtdIns(3,4,5)P3
levels. In turn, this is the result of a fine balance between class I PI3K activation and the action
of the enzyme Phosphatase and tensin homolog (PTEN), which dephosphorylates PtdIns(3,4,5)P3
at its 3-position, converting it back to PtdIns(4,5)P2 (Figure 3) [29]. Disruption of such a balance,
due to hyperactivation of class I PI3Ks or deletion/loss of function of PTEN, results in uncontrolled
accumulation of PtdIns(3,4,5)P3 and constant activation of Akt and Akt-dependent pathways and
cellular functions. Importantly, another PI3K product, PtdIns(3,4)P2, is also able to bind to the Akt
PH domain. Emerging evidence suggests that this phosphoinositide can have signaling functions
independently of PtdIns(3,4,5)P3, and it has been suggested to control Akt activity throughout the
endosomal membranes [30,31]. Interestingly, recent data [32] have indicated that the interaction of
calcium with PtdIns(3,4,5)P3 or PtdIns(3,4)P2 prevents membrane localization of PH domains of Akt,
phospholipase C-δ1 (PLCδ1), and insulin receptor substrate 1 [33].
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Figure 3. Schematic representation of the opposite action of class I PI3Ks and PTEN.
3. PI3Ks, PtdIns(3,4,5)P3, and Akt in Cancer
Deregulation of the class I PI3Ks/PtdIns(3,4,5)P3/Akt pathway occurs in several cancer types [19].
Activating mutations of class I PI3Ks, mainly of PIK3CA, the gene encoding the catalytic subunit p110α,
have been found in several cancer types along with copy number gains or amplification of class I
PI3Ks and alteration of the regulatory subunits [34]. Similarly, genetic and epigenetic alterations that
result in loss of PTEN function are very common in several cancer types [35]. Additional deregulation
normally found in many cancer types would also result in hyperactivation of class I PI3Ks-dependent
pathways, such as genetic alterations of receptor tyrosine kinases and other upstream regulators
of PI3Ks [35]. Due to its central role in promoting development and progression of several cancer
types, the PI3Ks/Akt pathway has been long recognized as an important target to develop novel
anti-cancer drugs [20,36,37]. Several inhibitors targeting different components of the pathway have
been developed over the years, from drugs targeting all PI3Ks or selective class I PI3K enzymes to
drugs targeting Akt or Akt downstream effectors, including mTOR [38]. Overall, however, the success
of these drugs has been somewhat disappointing, mainly because of limitations in the doses that can be
used to avoid affecting critical physiological functions and because of the development of mechanisms
of resistance [39]. Only a small number of these inhibitors are currently approved for use in specific
cancer settings, with more clinical trials and additional studies underway [40,41]. Studies to identify
novel strategies to block this pathway more efficiently and overcome these limitations are still required.
4. Inhibiting Akt by Targeting Its Mechanism of Activation
4.1. Preventing Akt Translocation to the Plasma Membrane
While many of the PI3Ks/Akt inhibitors compete with ATP, thus preventing the catalytic activity of
the kinases directly, identification of the PH domain-mediated mechanisms of activation paved the road
to the development of alternative strategies to inhibit Akt and its signaling pathways. In fact, the first
Akt inhibitor to enter clinical trial was perifosine, an alkyl-lysophospholipid (ALP), which was reported
to inhibit Akt translocation to the membrane and its subsequent phosphorylation [42]. Other ALPs,
such as edelfosine and miltefosine, were also found to be able to inhibit growth factor-induced Akt
activation [43]. Surface plasmon resonance spectroscopy studies ruled out a direct binding of perifosine
or edelfosine to purified Akt PH domain [44]. On the other hand, it was proposed that perifosine and
other ALPs might exert their effects by accumulating at the plasma membrane [45]. It has also been
suggested that a decreased content of plasma-membrane cholesterol might be partly responsible for
the reduced Akt activation [46].
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4.2. Targeting Akt PH/Kinase Domain Interaction
4.2.1. Allosteric Inhibitors
Several allosteric Akt inhibitors have been developed and brought to clinical trial [47].
Their development was mainly driven by the search for more specific drugs that could overcome
limitations due to off-target effects of ATP-competitive inhibitors. These drugs act by mainly targeting
the interaction between the PH and kinase domains. Examples include ARQ 092, ARQ 751 [48,49],
and BAY1125976 [50]. MK-2206 [51] is the most clinically advanced amongst the allosteric inhibitors
but has shown limited clinical activity as monotherapy in phase II trials [47,52].
4.2.2. Phosphatidylinositol Ether Lipid Analogues
While allosteric inhibitors mainly target the interaction of Akt PH domain with the kinase domain,
an alternative strategy has also been pursued, aiming at interfering with its binding to PtdIns(3,4,5)P3.
Phosphatidylinositol ether lipid analogues were designed to prevent Akt translocation to the plasma
membrane, mainly on the basis of the original demonstration that D-3-deoxy-3-substituted myo-inositols
appeared to inhibit growth of some transformed but not wild type NIH 3T3 cells [53]. This led to
the development of a series of 1-O-octadecyl-3-deoxy- or 3-hydroxymethyl-phosphatidylinositol
ether lipids and related carbonate analogues [54–56], as well as a strategy based on the use of
D-3-deoxy-phosphatidyl-myo-inositols that cannot be phosphorylated in the 3-position, which would
interfere with the correct PtdIns(3,4,5)P3/PH domain interaction [45]. Indeed, these compounds were
shown to bind to Akt PH domain, preventing its translocation to the plasma membrane and activation
of the enzyme [57].
4.2.3. Inositol Polyphosphates
As mentioned before, a very important feature of many PH domains is their ability to bind
water-soluble inositol polyphosphates, sometimes even with higher affinity than the corresponding
phosphoinositides [58]. For instance, we reported that the PH domain of the protein General receptor
for phosphoinositides, isoform 1, was able to bind PtdIns(3,4,5)P3, as well as its corresponding
inositol polyphosphate, Inositol 1,3,4,5-tetrakisphosphate (Ins(1,3,4,5)P4) (Figure 4) [33], consistent
with previous studies [59]. Similarly, we reported that PLCδ1 PH domain, which has a strong
affinity and specificity for PtdIns(4,5)P2, also binds the corresponding Inositol 1,4,5-trisphosphate
(Ins(1,4,5)P3) (Figure 4) [33], consistent with previous studies [60]. Similarly, Akt PH domain was
found to bind to Inositol 1,3,4,5,6-pentakisphosphate (InsP5), and to a slightly lesser extent to Inositol
1,4,5,6-tetrakisphosphate (Ins(1,4,5,6)P4) [58].
Twenty years ago, we proposed that such a feature could be exploited as an alternative strategy
to block the interaction between phosphoinositides and PH domains, as water-soluble inositol
polyphosphates could be delivered intracellularly and compete with phosphoinositides for PH domain
binding [61]. In particular, we proposed that inositol polyphosphates that could compete with
PtdIns(3,4,5)P3 for its binding to Akt PH domain might block activation of this protein kinase. In our
original study, we demonstrated that treatment of COS7 cells with exogenous Ins(1,4,5,6)P4 was indeed
able to inhibit translocation of a Green fluorescent protein (GFP)-tagged Akt PH domain to the plasma
membrane [62], providing one of the first pieces of evidence that water-soluble inositol polyphosphates
could prevent Akt membrane targeting. Consistent with the inhibition of Akt translocation, exogenous
Ins(1,4,5,6)P4 and InsP5 were the only inositol polyphosphates able to inhibit proliferation/growth of
breast cancer cell line MCF7 and small cell lung carcinoma (SCLC) cell line H69. No effect was detected
when cells were treated with Ins(1,4,5)P3, Ins(1,3,4,5)P4, or Inositol 1,2,3,4,5,6-hexakisphosphate (InsP6),
whereas treatment with inositol 3,4,5,6-tetrakisphosphate (Ins(3,4,5,6)P4) resulted in ~25% inhibition.
These data indicated a specific effect of selective inositol polyphosphates, likely those able to bind to
Akt PH domain [62]. As a further confirmation of this hypothesis, Ins(1,4,5,6)P4 affected growth of the
ovarian cancer SKOV-3 cells, which are characterized by constitutive PI3K activation, but not growth
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of colon carcinoma SW620 cells, which does not depend on PI3K [62]. This original study prompted us
to propose a mechanism by which Ins(1,4,5,6)P4 and InsP5 were able to block Akt recruitment to the
membrane by binding to its PH domain and competing with PtdIns(3,4,5)P3.
Figure 4. Schematic representation of phosphoinositides and their corresponding
inositol polyphosphates.
Subsequent studies further confirmed the anti-cancer properties of InsP5. First, we demonstrated
that InsP5 induced apoptosis of (SCLC)-H69 cells and SKOV-3 cells [63]. Neither InsP6, Ins(3,4,5,6)P4,
nor Ins(1,4,5,6)P4 were able to induce apoptosis SCLC-H69 cells. Importantly, InsP5 proved to be as
potent as etoposide in SCLC-H69 cells and as cisplatin in SKOV-3 cells. Consistent with our hypothesis
of a competition with PtdIns(3,4,5)P3, InsP5, but not Ins(3,4,5,6)P4 or Ins(1,4,5,6)P4, inhibited Akt
phosphorylation at Ser473 or phosphorylation of the Akt downstream effector Glycogen synthase
kinase 3 in SKOV-3 cells. The fact that overexpression of a myristoylated, constitutively active Akt
blocked the pro-apoptotic activity of InsP5 further confirmed its mechanisms of action [63].
The ability of InsP5 to inhibit Akt activation was not limited to cancer cell lines, as this was
also observed in PTEN–/– embryonic stem cells [63] and in human umbilical vein endothelial cells
stimulated with basic fibroblast growth factor (FGF-2) [64]. In both cases, treatment with other inositol
polyphosphates had no effect. Consistent with the inhibition of the PI3K/Akt pathway, InsP5 inhibited
FGF-2-induced cell survival to the same extent as two Akt inhibitors [64]. This study further revealed that
InsP5, but not other inositol polyphosphates tested, reduced the FGF-2-mediated cell migration, capillary
tube formation in vitro, and angiogenic response in vivo. The pro-apoptotic and anti-angiogenic
properties of InsP5 resulted in strong anti-tumor activity in vivo, confirmed by reduced tumor growth
upon treatment with InsP5 but not with InsP6 in a xenograft model of SKOV-3 cells. Importantly,
InsP5 reduced tumor growth to the same extent as cisplatin and inhibited Akt activation in vivo,
as assessed by analysis of dissected tumors. In this respect, this study provided the first demonstration
that exogenous InsP5 could inhibit tumor growth and Akt phosphorylation in vivo [64]. Evidence of
an endogenous regulation of Akt activation by highly phosphorylated inositol polyphosphates also
appeared, as was the case in a study reporting that genetic ablation of the inositol hexakisphosphate
kinase IP6K1, one of the enzymes responsible for synthesis of 5-diphosphoinositolpentakisphosphate
(5-InsP7), resulted in increased Akt signaling in mouse embryonic fibroblasts upon stimulation with
Int. J. Mol. Sci. 2020, 21, 7198 8 of 16
insulin-like growth factor 1, as well as in gastrocnemius muscle, epididymal white adipose tissue,
and primary hepatocytes in response to acute insulin treatment [65]. The authors further showed
that 3H-InsP7 was able to bind to full-length Akt, while binding to a mutant Akt lacking the PH
domain was strongly reduced [65], supporting the conclusion that endogenous InsP7 can compete
with PtdIns(3,4,5)P3 for binding to the Akt PH domain.
5. Improving the Activity of InsP5—Chemical Modifications
5.1. Chemical Modifications that Resulted in Inhibition of Additional and Selective Targets
Once we confirmed that the inositol polyphosphates-dependent strategy was successful in
blocking Akt activation in vitro and in vivo, we focused our attention on the possibility of improving
the anti-cancer activity of InsP5 by designing novel synthetic compounds based on the structure of
this inositol polyphosphate. Modifications were made on either the 2-O-atom or the 5-phosphate,
thus maintaining the symmetry of the parent molecule, and this led us to identify the derivative
2-O-benzyl-myo-inositol 1,3,4,5,6-pentakisphosphate (2-O-Bn-InsP5) as the most efficient of those
tested (Figure 5) [66].
Figure 5. Schematic representation of InsP5 and its derivative 2-O-Bn-InsP5.
Characterization of this compound confirmed that it was able to inhibit the platelet-derived
growth, factor-induced conformational change of a GFP/Red fluorescent protein-tagged-Akt, resulting
in reduced Akt phosphorylation in NIH 3T3 cells overexpressing PDK1 and Akt [67]. Moreover,
2-O-Bn-InsP5 proved to be more efficient than the parental molecule at reducing Akt phosphorylation,
inhibiting cell growth and inducing apoptosis in cell lines that are sensitive to InsP5, such as SKOV-3
and SKBR3 cells [66]. Furthermore, 2-O-Bn-InsP5 was able to inhibit Akt phosphorylation and growth
of cell lines normally resistant to InsP5, such as prostate cancer PC3 cells and pancreatic cancer ASPC1
cells [66]. More importantly, 2-O-Bn-InsP5 inhibited growth of PC3 cells in a xenograft model, whereas
InsP5, used at the same doses, had no effect. The anti-cancer activity in vivo was mirrored by reduced
Akt phosphorylation in dissected tumors. This study demonstrated that the addition of a benzyl group
to the axial 2-O atom of InsP5 resulted in enhanced pro-apoptotic and anti-tumor properties [66].
Interestingly, 2-O-Bn-InsP5 was found to be able to inhibit PDK1 activity in vitro, with an IC50 in
the low nanomolar range [66]. Further investigation confirmed that 2-O-Bn-InsP5 was able to bind to
PDK1 PH domain with an affinity of 109± 44 nM and a 1:1 stoichiometry [67]. These data led us to
conclude that 2-O-Bn-InsP5 was more efficient than its parental molecule, likely because of its ability
to target Akt and PDK1 simultaneously and therefore to inhibit additional PI3K/PDK1-dependent,
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Akt-independent pathways. In this respect, it is noteworthy that we further demonstrated that,
alongside Akt inhibition, 2-O-Bn-InsP5 inhibited the formation of a protein complex between PLCγ1
and PDK1 [67], a complex we had previously reported as being important for breast cancer cell
migration and invasion [68]. Specifically, we demonstrated that 2-O-Bn-InsP5 reduced the epidermal
growth factor-induced translocation of both enzymes to the plasma membrane and PLCγ1 activation,
resulting in inhibition of cell migration and invasion in a panel of cancer cells as well as metastasis
dissemination in a zebrafish embryo model [67].
These studies represented an important step forward in the development of inositol
polyphosphate-based drugs. Indeed, one of the main concerns towards the use of inositol
polyphosphates is the possibility that they might interfere with additional phosphoinositide-dependent
signaling, resulting in non-specific effects. In this respect, our demonstration that 2-O-Bn-InsP5 was
able to inhibit a very specific, PDK1-mediated mechanism of PLCγ1 activation, without interfering with
the normal regulation of this enzyme, proved that it is possible to modify the structure of an inositol
polyphosphate and to synthesize compounds that can target enzymes in a more selective manner.
5.2. Chemical Modifications That Increase Intracellular Delivery
While evidence demonstrating the anti-cancer activity of InsP5 accumulated, the crucial
question concerning its exact mechanism of action and, specifically, the precise mechanism of
its incorporation/cellular uptake, remained to be addressed. Efficient incorporation of inositol
polyphosphates, in particular of Ins(1,3,4,5)P4, was already reported in our original study where
starved H69 cells were incubated with 3H-Ins(1,3,4,5)P4 together with 50mM unlabeled Ins(1,3,4,5)P4
for 20 min, and the levels of 3H-inositol polyphosphates within the cells and in the extracellular medium
were measured by HPLC [62]. This analysis not only confirmed incorporation of 3H-Ins(1,3,4,5)P4 but
it also indicated that ~45% of this compound was converted into distinct metabolic products in the
timeframe of the experiment [62]. We later confirmed that incubation of SKOV-3 cells with 32P-InsP5
for different times resulted in an efficient and time-dependent incorporation of the radiolabeled
compounds, as assessed by HPLC analysis [64]. Moreover, we observed a slow turnover of InsP5
with only 5.0% of the total being converted into different metabolites after 30 min of incubation
and only 6.2% converted after 1 h of incubation. The slow turnover of InsP5 was confirmed by
pulse-chase experiments in SKOV-3 cells that revealed that 84.6% of total 3H-InsP5 but only 7% of
total 3H-Ins(1,3,4,5)P4 was still detectable intracellularly after 5 h [37]. The mechanism of inositol
polyphosphate incorporation is still not completely understood. A study investigating internalization
of exogenous InsP6 in HeLa cells proposed it to occur via pinocytosis [69]. A transporter was also
identified in Arabidopsis [70], but further studies are required to establish the precise mechanism of
incorporation/uptake.
During our studies, we observed that uptake of inositol polyphosphates differed between cell
lines (Maffucci and Falasca, unpublished observations). This observation led us to hypothesize that
increasing InsP5 intracellular uptake could represent an alternative strategy to potentiate its activity.
Indeed, some preliminary data in our laboratory indicated that a hydrophobic pro-drug of InsP5
(Bt- InsP5 PM, SiChem, Bremen, Germany), which could enter cells by diffusion, showed increased
activity (as assessed by cell counting after 72h treatment) compared to the parental molecule (Maffucci
and Falasca, unpublished observations). This was observed not only in cells sensitive to InsP5, such
as SKOV-3 and SKBR3 (IC50 4.5 and 4.8 µM for Bt- InsP5 vs. 23 and 21 µM for 2-O-Bn-InsP5 and
<50 µM for InsP5), but also in cells more resistant to treatment with InsP5, such as PC3, ASPC1, PANC1,
and MDA-MB-468 cells (IC50 27.6, 14.7, 11.2, and 16.9 µM, respectively vs. IC50 <50 µM; Maffucci
and Falasca, unpublished observations). These preliminary observations suggest that the anti-cancer
activity of InsP5 can be greatly increased by improving its intracellular delivery.
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5.3. Nanodelivery
Efficient delivery within the cell is one of the main issues with inositol polyphosphates or inositol
polyphosphate analogues. In this respect, nanomedicines, which can target drugs at the site of
action, might represent an interesting and valuable strategy. The availability of delivery systems
provides an unprecedented opportunity to encapsulate variety of drugs, including negatively charged
molecules, with high loading capacity and improved oral delivery. Therefore, it would be interesting to
explore the possibility that nanodelivery strategies might improve the therapeutic potential of inositol
polyphosphates, as it has been successfully achieved for other Akt/PDK1 inhibitors [71,72].
6. Targeting PH Domains of Signaling Proteins: Beyond Akt
Although the interest on PH domain inhibitors has been mainly polarized by Akt PH domain,
other PH domain-containing signaling proteins have been shown to be potential targets. As mentioned
before, 2-O-Bn-InsP5 binds to PDK1 PH domain and inhibits the assembly of a protein complex
between PLCγ1 and PDK1. More recently, we found that 2-O-Bn-InsP5 inhibits 2D and 3D growth of
different pancreatic cancer cell lines but not 2D growth of normal pancreatic cells, and it potentiates the
activity of inhibitors of the PI3K isoform p110γ [73]. In addition, it has been found that introduction of
WT-TP53 increased the sensitivity of human pancreatic cancer cell line MIA-PaCa-2 to 2-O-Bn-InsP5 [74].
Subsequently, it has been shown that β-estradiol strongly potentiated 2-O-Bn-InsP5 efficacy to inhibit
the growth of human pancreatic cancer cell lines BxPC3 and MIA-PaCa-2 [75]. Taking into consideration
the potential role of PDK1 in the development of chemoresistance in different cancer types, this evidence
suggests that targeting PDK1 PH domain promotes chemosensitization [76]. Bruton ‘s tyrosine kinase
(Btk) and Interleukin-2-inducible T cell kinase (Itk) are known to play a key role in B cell and T
cell receptor signaling, respectively [77]. Both Btk and Itk are localized in the cytoplasm in resting
cells and translocate to the plasma membrane upon receptor activation through binding of their PH
domains to PtdIns(3,4,5)P3 [78]. Small compounds targeting the interaction between Btk PH domain
and PtdIns(3,4,5)P3 have been developed [79]. Interestingly, inositol polyphosphates have been found
to regulate both Btk and Itk through PH domain binding [79–81]. Similarly, compounds targeting
the PH domain of the PtdIns(3,4,5)P3-dependent Rac exchanger 1 have been recently developed and
tested in vitro and in vivo, demonstrating that this PH domain is a drug target [82]. Strategies using in
silico screening of a library of compounds to identify possible PH domain ligands have been recently
developed. A successful example is the identification of a PH domain-binding molecule (PHT-7.3) as a
candidate inhibitor of the scaffold protein connector enhancer of kinase suppressor of Ras 1 (Cnk1)
through molecular modelling. Remarkably, PHT-7.3 has been shown to inhibit Cnk1 plasma membrane
co-localization with KRas mutant and to block KRas-dependent cell growth in vivo and in vitro [83].
7. Conclusions
Over the past 20 years, our work has contributed to establishing inositol polyphosphates
as promising leading compounds to design Akt inhibitors that specifically prevent its
PtdIns(3,4,5)P3-dependent plasma membrane translocation. Our studies not only identified
the anti-cancer properties of InsP5, but they also indicated strategies to improve its activity.
Our demonstration that chemical modifications can lead to compounds with increased selectivity
towards other components of the PI3K-dependent signaling pathways represents an important step
forwards for development of more specific inhibitors that might overcome limitations due to potential
non-specific effects of inositol polyphosphates. On the other hand, our data also indicate that strategies
that increase their intracellular uptake or delivery (chemical modification and/or complex formation)
might result in more efficient anti-cancer activity. In this respect, a better understanding of the
mechanisms of inositol polyphosphate uptake would provide crucial information to exploit their
therapeutic potential fully.
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In addition, structural biology can provide crucial insight, currently not fully appreciated,
in the interactions between inositol polyphosphates and PH domains that can lead to the
discovery of novel drug candidates [84]. In this respect, the combination of crystallography,
molecular modelling, mutagenesis, structure-activity relationship and membrane-binding assays [85]
can provide novel opportunity in the development of drugs specifically targeting the PH
domain–phosphoinositides interaction.
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